Novartis pays $1B upfront for PTC’s Phase 2 Huntington’s drug

No­var­tis is re­turn­ing to Hunt­ing­ton’s dis­ease with a $1 bil­lion up­front bet, plus an­oth­er $1.9 bil­lion in biobucks, for ac­cess to a Phase 2 oral …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.